Business
LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 0896H AstraZeneca PLC 05 June 2017 \n\n5 June 2017 07:00 BST \n \nLYNPARZA SIGNIFICANTLY REDUCES THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH BRCA-MUTATED METASTATIC BREAST CANCER\n \nOlympiAD was the first positive Phase III trial to evaluate the\nefficacy and safety of a PARP inhibitor beyond ovarian cancer\n \nLynparza tablets reduced risk of disease worsening or death by 42%\n \nThe overall safety profile was consistent with previous trials of Lynparza\n \n \nAstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician's choice of a standard of care chemotherapy. In addition to meeting its primary endpoint of PFS assessed by blinded independent central review (BICR), the trial showed that patients treated with Lynparza had a 42% reduction in risk of their disease worsening or death (HR 0.58; 95% CI 0.43-0.80; p=0.0009; median 7.0 vs 4.2 months) compared to those who received chemotherapy (capecitabine, vinorelbine, eribulin). \n \nThe data were presented at the 2017 ASCO Annual Meeting in Chicago, during today's Plenary Session from 15:10-15:25 CDT (Abstract LBA4).[i] The trial was designated for the \"Best of ASCO\" selection, underscoring the importance of these results for patients and physicians, and the results are published in the New England Journal of Medicine. \n \nMark E. Robson, Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center, New York and Principal Investigator of OlympiAD said, \"The OlympiAD data presented today demonstrate the benefit of olaparib in delaying the progression of advanced BRCA-mutated breast cancer. With few alternatives available, a targeted non-chemotherapy oral treatment in this setting could be a beneficial new option for patients.\"\n \nSean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said, \"The OlympiAD results shared today mark the first time a targeted therapy shows benefit over the current standard of care for patients with HER2-negative gBRCA-mutated m...